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Abstract
African Americans have been understudied in genome wide association studies of diabetes and related traits. In the current
study, we examined the joint association of single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) with
fasting insulin and an index of insulin resistance (HOMA-IR) in the HyperGEN study, a family based study with proband
ascertainment for hypertension. This analysis is restricted to 1,040 African Americans without diabetes. We generated allele
specific CNV genotypes at 872,243 autosomal loci using Birdsuite, a freely available multi-stage program. Joint tests of
association for SNPs and CNVs were performed using linear mixed models adjusting for covariates and familial relationships.
Our results highlight SNPs associated with fasting insulin and HOMA-IR (rs6576507 and rs8026527, 3.7*10
27#P#1.1*10
25)
near ATPase, class V, type 10A (ATP10A), and the L Type voltage dependent calcium channel (CACNA1D, rs1401492,
P#5.2*10
26). ATP10A belongs to a family of aminophospholipid-transporting ATPases and has been associated with type 2
diabetes in mice. CACNA1D has been linked to pancreatic beta cell generation in mice. The two most significant copy
variable markers (rs10277702 and rs361367; P,2.0*10
24) were in the beta variable region of the T-cell receptor gene
(TCRVB). Human and mouse TCR has been shown to mimic insulin and its receptor and could contribute to insulin
resistance. Our findings differ from genome wide association studies of fasting insulin and other diabetes related traits in
European populations, highlighting the continued need to investigate unique genetic influences for understudied
populations such as African Americans.
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Introduction
Long term insulin resistance is the major precursor to type 2
diabetes (T2D), a condition which currently affects more than
10% of Americans older than 20 years of age [1,2]. Insulin
resistance is a complex disorder influenced by lifestyle and genetic
factors where the natural hormone, insulin, becomes less effective
at lowering high blood sugar. When a compensatory increase in
insulin secretion does not occur, blood glucose concentrations
increase and set the stage for progression to T2D [3]. While there
are various tests used to detect insulin resistance, fasting insulin
levels and the Homeostasis Model Assessment Insulin Resistance
Index (HOMA-IR) are widely used in population based studies
[4]. Based on these measures, the risk of developing insulin
resistance and subsequent T2D varies between different ethnic
populations and is at least two times greater among African
Americans compared to Caucasians [3].
African Americans have been severely under-represented in
genome wide association studies (GWAS) of T2D and/or related
traits [5]. There is a need for such studies as replicated variants
derived from Caucasian samples have not consistently generalized
to T2D related risk in African Americans [6–8]. This could be due
to different disease pathology with unique genetic risk variants
amongst African Americans or reflect differences in allele
frequencies or patterns of linkage disequilibrium [6,9–11].
Current generation single nucleotide polymorphism (SNP)
genotyping arrays have been designed to assay copy number
variants (CNVs), a type of structural variant which may explain
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24052additional genetic variability associated with complex human traits
[12,13]. A recent report from the Wellcome Trust Case Control
Consortium questioned the added value of analyzing common
copy number variation (that can be genotyped on existing
platforms) in genome wide studies of SNPs. Specifically, they
identified several CNV loci that are associated with common
disease (including T2D) and showed those CNVs were generally
well tagged by nearby SNPs [14]. However, those conclusions
were based on data from populations of European ancestry. Thus,
it is unclear if CNVs (assayed on existing platforms) are well tagged
by SNPs in African American populations given higher degrees of
recombination and shorter spans of linkage disequilibrium in
comparison to European populations [9].
Methods using the software package Birdsuite have been
developed to concurrently analyze SNP and CNV polymorphisms
assayed on the Affymetrix 6.0 platform [15]. Additionally,
research has effectively shown targeting quantitative traits in
normoglycemic populations in GWAS searches can help identify
genetic determinants of overt disease [16]. Therefore, in this study
we performed joint tests of association between SNPs and CNVs at
the genome-wide level with fasting insulin and HOMA-IR in
1,040 African American participants without diabetes in the
Hypertension Genetic Epidemiology Network (HyperGEN) study.
Methods
Ethics Statement
The study was approved by the University of Alabama at
Birmingham’s Internal Review Board for Human Use, the
Washington University Human Research Production Office, the
University of North Carolina’s Office of Human Research Ethics
and the Medical College of Wisconsin’s Office of Human
Research Protection Program. All subjects provided written
informed consent. The study conforms with the principles outlined
in the Declaration of Helsinki, and all procedures followed were in
accordance with institutional guidelines.
Study Population
Study participants were enrolled in the HyperGEN (Hyperten-
sive Genetic Epidemiology Network) study. HyperGEN is part of
the Family Blood Pressure Program funded by the National Heart
Lung and Blood Institute and was designed to study the genetics of
hypertension and related conditions. Participants were recruited
from multiply-affected hypertensive sibships ascertained through
population-based cohorts or from the community-at-large. The
study was later extended to include siblings and offspring of the
original sibpair. Probands were identified by the onset of
hypertension before age 60 and the presence of at least one
additional hypertensive sibling who was willing to participate.
Participants with type 1 diabetes or advanced renal disease
(defined as serum creatinine level .2 mg/dL) were excluded from
the original study since these two conditions can cause secondary
hypertension and the goal of HyperGEN was to identify novel
essential hypertension loci. Recruitment, cross-sectional clinical
measurement, and DNA isolation were completed in 2003. Two of
four centers (AL, NC) recruited 1,264 African Americans, while
three centers (NC, MN, and UT) recruited Caucasians [17].
Persons reporting treatment with insulin or oral hypoglycemic
agents were excluded from the current study (N=212).
Laboratory Measures
Insulin measured after at least 8 hours of fasting was recorded
for all participants in HyperGEN. Samples were collected in a
resting state for insulin concentration using an automated
immunoassay instrument (Beckman Coulter, Fullerton, CA,
USA) [18]. HOMA-IR was calculated as (fasting insulin x (fasting
glucose x 0.056))/22.3, with glucose in the units of mg/dL, and
insulin in the units of mIU/L. The measurement of fasting glucose
in HyperGEN has been described [19].
Genotyping
DNA extraction and purification from HyperGEN has been
described in Williams et al. (2000) [17]. Genotyping was performed
using the Affymetrix Genome-Wide Human SNP 6.0 Array
following the Affymetrix defined protocol. Genotypes were called
using Birdsuite, an open-source set of tools developed at the Broad
Institute [15]. Birdsuite is multi-stage analytical framework that
determines allele specific copy number calls at each locus. The
Larry Bird application in Birdsuite generates integrated SNP/CNV
genotype calls ranging from 0–4 copies of each allele.
Quality Control
A total of 909,622 markers were assayed. The median marker
call rate was 99.97%. The overall Mendelian inheritance error
rate was 0.04%. We removed SNPs due to excessive missingness
(.1%; N=282), low minor allele frequency (,1%; N=21,875),
or evidence for deviation from Hardy-Weinberg equilibrium in
founders (P,0.0001; N=15,222). All marker locations are based
on the hg18 reference genome assembly.
While the error rates for SNP genotypes are typically small
(,1%), the corresponding rates for array-based detection of CNV
are considerably larger and dependent on the CNV size and
frequency [15,20]. Thus, we only considered CNVs with
frequency .1% and, based on the Birdsuite developer’s recom-
mendations, confidence values less than 0.1 in this report [15].
Statistical Methods
Genetic admixture can both confound population association
studies [21] or produce spurious results [22–25]. As a proxy for the
degree of global European ancestry, in our African American
population we generated principal components (PCs) from all
872,243 SNPs using Eigenstrat [26]. Based on the examination of
the scree plot [27] (Figure S1) the first four PCs were retained and
used as covariates for all association analyses.
Joint tests of association for allelic and copy number variation
with fasting insulin levels and HOMA-IR were conducted on all
872,243 autosomal SNPs passing quality control thresholds. These
joint models were analogous to that proposed by Korn et al., with
the exception of including random effects for each family [28].
Because it was not computationally feasible to fit a linear model
including random effects for all 872,243 loci, we performed a two-
stage procedure using the genome-wide rapid association using
mixed model and regression (GRAMMAR) approach introduced
by Aulchenko et al [29]. In stage 1, residuals measuring the log-
transform (to achieve normality of residuals) of measures of insulin
resistance were generated via a mixed model after controlling for
relatedness and fixed effect covariates. In terms of the present
study:
b ei ei~ln Yi ðÞ { b a az
X 4
j~1
b qj qj:PCi,jz b q5 q5:ageiz b q6 q6:sexizb ci ci:familyi
"#
~Y 
i
ð1Þ
where, wj,j~1,...,4 are the fixed effects from the first four
principal components obtained from Eigenstrat to control for
admixture, w5 and w6 are the fixed effects for age and sex, and ci is
{1}
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equation 1 were obtained from the PROC MIXED procedure in
SASH software, Version 9.2 (SAS, Cary NC). The resulting
residuals (Y 
i ) for the ithsubject were then regressed against his or
her allelic and copy number state at each locus in a linear model:
Y ~azb1 A{B ðÞ zb2 AzB ðÞ ze: ð9Þ
In equation 2, A is the number of A alleles at the locus, B is the
number of B alleles at the locus, b1 corresponds to an additive
allelic effect, while b2 represents an additive copy number effect.
The joint test involves assessing the null hypothesis,
H0 : b1~b2~0. When either SNP allele or copy number state
is invariant, the model defaults to a single test of either allelic or
copy number effect: b1 =0orb2 =0, respectively. Analyses of the
residuals in equation 2 was performed via lm function using R
version 2.8.0 (R development core team, 2008).
In stage 2, the markers corresponding to the top 1,000 most
significant findings from stage 1 were then re-analyzed using the
full mixed model (for the log-transform of Y) [30]. The full mixed
model used for analysis can be written as:
Y~azb1 A{B ðÞ zb2 AzB ðÞ z
X 4
j~1
wj PCj
  
zw5 Age ðÞ zw6 Sex ðÞ zci family ðÞ ze
The parameters in equation 3 correspond to those described
above. Models in the second stage were obtained using the lmer
function in R.
The UCSC Genome Browser was used to locate genes within
200 kilobases (kb) up or downstream of loci that were significantly
associated with our phenotypes [31]. The Gene Sorter program
was then used to identify expression patterns, homology and other
information on the identified genes [32].
Results
The mean age of the population was 43.5613 years, the
majority of participants were female (66%) and recruited in
Alabama (79%). The mean fasting glucose in our study population
was 95616 mg/dL (5.260.9 mmol/L). The average fasting
insulin measure was 10.268 mIU/mL (70.8655 pmol/L) and
5% of the study population had fasting insulin surpassing the
upper level of the normal range (3–25 mIU/mL) [33,34]. The
average fasting HOMA-IR was 2.562 (no units).
The first stage of the GRAMMAR procedure conservatively
tests the hypotheses of association [29]. For each outcome the first
stage results obtained for all 872,243 loci were used as a screening
tool to identify possible associations. From these results, the 1,000
markers with the smallest P-values were tested in the second stage.
These markers were fit into the full model described in Equation
{3}. In Table 1 we report the most significant markers derived
from the full model for each outcome. For both fasting insulin and
HOMA-IR the most significant findings were not copy number
variable and the model defaulted to a model of SNP effects.
Detailed results for all markers analyzed in the second stage
analysis are presented in Table S1. Fasting insulin and HOMA-
IR were positively correlated with r=0.96 and we found several
markers with evidence of association with each trait (Table S1).
Two markers highlighted in Table 1 (rs1401492 and rs6576507)
were among the top results for both traits. Overall, none of the
observed markers reached the typically utilized threshold for
genome-wide significance (P,5*10
-8). Nonetheless, our analyses
do highlight some biologically interesting regions with suggestive
evidence of association.
Among the markers we analyzed, 35% were identified as copy
number variable in this dataset. For fasting insulin we identified 13
markers where the CNV effect showed a trend toward significance
(PCNV#9*10
24). However, most of these associations were
influenced by CNVs at low frequency in the cohort (,1%).
Results for HOMA-IR were similar. As this is the first GWAS of
insulin resistance in African Americans to include analysis of copy
number variation that we are aware of, we highlight frequent
(.1%) copy variable markers with PCNV#9*10
24 in Table 2. The
copy number variable region on Chromosome 7q34 associated
with both outcomes is interesting for follow-up. Two nearby
markers (rs10277702 and rs361367) are informed for copy number
variation by 21 surrounding probes. Both markers correspond to a
deletion present in 23 participants and both CNVs are positively
associated with fasting insulin and HOMA-IR.
Discussion
Using the Affymetrix Genome-Wide Human SNP Array 6.0 we
analyzed the joint effect of SNPs and CNVs with measures of
insulin resistance in 1,040 African American participants from the
HyperGEN study that had no personal history of diabetes. The
majority of GWAS findings to date highlight variants associated
with fasting glucose and diabetes status rather than fasting insulin
and HOMA-IR levels [16,35,36]. We found no evidence of
association of fasting glucose or diabetes related loci from recent
Table 1. Top loci associated with fasting insulin [ln(mIU/mL)]
and HOMA-IR in African Americans without diabetes from
HyperGEN.
Marker
{ Chr A1
{/A2 MAF Gene*
% effect
(95% CI) P-Value
Insulin
rs6576507 15 A/G 0.13 ATP10A 14 (8,20) 4*10
27
rs8026527 15 A/G 0.13 ATP10A 14 (8,20) 6*10
27
rs12655917 5 C/T 0.01 AP3B1 240 (251, 227) 6*10
27
rs4819143 21 C/T 0.06 PCBP3 217 (223, 210) 1*10
26
rs17431357 12 C/T 0.01 TRIAP1 234 (244, 222) 1*10
26
rs2407103 8 C/T 0.09 KCNU1 15 (9,23) 2*10
26
rs1401492 3 C/T 0.07 CACNA1D 215 (221, 29) 3*10
26
rs591044 22 A/G 0.37 SEZ6L 9 (5,13) 6*10
26
rs604459 22 C/T 0.38 SEZ6L 8 (5,12) 8*10
26
HOMA-IR
rs7043482 9 G/T 0.19 - 12 (7, 18) 3*10
26
rs17589516 6 C/T 0.02 ZFAND3 45 (24, 69) 4*10
26
rs9792548 9 C/T 0.15 GAS1 212 (216, 27) 4*10
26
rs1401492 3 C/T 0.07 CACNA1D 216 (222, 29) 5*10
26
rs16962638 13 C/T 0.11 - 15 (8, 22) 6*10
26
rs6576507 15 A/G 0.13 ATP10A 13 (7, 20) 7*10
26
rs2407314 8 C/G 0.47 CSMD1 29( 212, 25) 8*10
26
{For more detailed information about these markers see Table S1.
{A1 is the modeled and minor allele.
*nearest gene within a 200 kb window on either side of the marker (if gene is
italicized the marker lies in the gene).
doi:10.1371/journal.pone.0024052.t001
{2}
{3}
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from HyperGEN. Variants associated with fasting insulin (and
HOMA-IR) with significance at the genome wide level in
European populations include the glucokinase regulatory protein
gene (GCKR) and insulin-like growth factor 1 (IGF1). In our study,
markers in these genes were not associated with fasting insulin or
HOMA-IR (P.0.05) nor did any of our top hits from Table 1
replicate in a large cohort (N.40,000) of persons of European
ancestry from the MAGIC consortium (P.0.2) [16]. While some
loci, e.g., transcription factor 7-like 2 (TCF7L2), are associated
with diabetes and related traits across racial populations, the
majority of studies, including ours, have not replicated risk loci
across these two racial groups [6–8,37].
In agreement with published GWAS [16,35,36] the magnitude
of effect for markers of interest (Table 1) is generally small
[16,35]. However, we found some biologically plausible associa-
tions that approached significance in our study. Among the top
hits shared by both traits are loci (rs6576507, rs8026527) 180 kb
downstream of ATPase, class V, type 10A (ATP10A). ATP10A
belongs to the subfamily of aminophospholipid-transporting
ATPases. One study reported an unusual pattern of maternal
inheritance of the chromosomal region containing the gene (also
referred to as ATP10c) was associated with obesity, T2D, and
nonalcoholic fatty liver disease in mice [38]. The marker
rs1401492 is highlighted in Table 1 for both traits and lies in
intron 3 of the L Type voltage dependent calcium channel
CACNA1D (chr3:53,504,071–53,821,532). CACNA1D has been
shown to be induced by a high fat diet [39] and required for
pancreatic beta cell generation in mice [40]. Other interesting
markers highlighted in Table 1 include rs12655917 and
rs17431357 for fasting insulin just upstream (,6kb) of the beta 1
subunit of the adaptor-related protein complex 3 (AP3B1) and the
of p53-inducible cell-survival factor (TRIAP1), respectively. AP3B1
is involved in the subcellular trafficking of vesicular cargo proteins
[41]. It is lowly expressed in pancreatic islets (where insulin
secreting beta cells reside) and, could play a role in insulin
secretion [32]. TRIAP1 prevents induction of apoptosis and is
expressed in the pancreas and islets. Pancreatic beta-cell death by
apoptosis contributes significantly to both autoimmune type 1
diabetes and type 2 diabetes [42]. Top results for HOMA-IR
include markers near growth arrest specific gene 1 (GAS1) and
CUB and Sushi multiple domains 1 (CSMD1). GAS1 is a cell cycle
inhibiting protein that has been linked to cancer and CSMD1 has
been associated with hypertension and peripheral artery disease in
GWAS of persons of Asian descent [43–45].
The effect size for copy variable markers presented in Table 2
(on the order of 30–40%) is similar to the effect size for SNPs of the
same frequency (MAF 1–2%) from Table 1. The markers
rs10277702 and rs361367, most significantly associated with both
outcomes, lie in the well characterized T-cell receptor beta
variable region (TCRVB, chr7:141,695,793–142,058,637) [46].
The copy number variable regions of T-cell receptors (TCR) have
been sequenced for a variety of autoimmune diseases. One study
reported that TCR from humans with diabetes and non-obese
mice with diabetes mimic insulin and the insulin receptor. These
data could explain how insulin, and its receptor are targets of
autoimmunity in diabetes [47]. This data are interesting for follow-
up given the accumulating evidence of immune system involve-
ment in the pathophysiology of type 2 diabetes [48] and provide a
potential link to the pathology of insulin resistance in African
Americans.
This study population was ascertained on hypertension status
and antihypertensive treatment has been associated with changes
in glucose homeostasis [49]. In our study population, 15%, 25%
and 33% were treated with an ACE inhibitor, calcium channel
blocker and diuretic, respectively, and these variables were
associated with our measures of insulin resistance (P,0.1).
Treatment with a beta blocker or alpha blocker was not associated
with either outcome. Additionally, insulin resistance is strongly
associated with obesity through common pathways such as
inflammation [50]. Thus, we considered models adjusted for body
mass index and the antihypertensive treatments described aiming
to uncover novel findings and/or stronger effects for discovered
variants. The results are presented in Table S2 and largely show
adjusting for these additional factors uncovered association with
many of the same markers as reported in this manuscript (and
Table S1) with decreased significance. For example, rs8026527
and rs6576507, the top hits for fasting insulin (P,6*10
27), were
also positively associated with fasting insulin for the fully adjusted
model with P,2*10
25.
We implemented the GRAMMAR method for quantitative
traits specific for family data described by Aulchenko et al. [29]
Table 2. Top copy variable loci associated with fasting insulin
[ln(mIU/mL)] and HOMA-IR in African Americans without
diabetes from HyperGEN.
Marker
{ Chr
A1
{/
A2 Gene* Effect Freq
{ % Effect P-Value
Insulin
rs10277702 7 C/T TCRVB SNP 0.49 21( 24,3) 0.57
CNV 0.02 246
(261, 227)
1*10
24
Joint 4*10
24
rs361367 7 C/T TCRVB SNP 0.42 0 (24,3) 0.81
CNV 0.02 245
(260, 225)
2*10
24
Joint 8*10
24
rs12552047 9 C/G - SNP 0.01 225
(236, 212)
3*10
24
CNV 0.01 247
(264, 223)
9*10
24
Joint 1*10
24
HOMA-IR
rs10277702 7 C/T TCRVB SNP 0.49 22( 25, 2) 0.39
CNV 0.02 252
(266, 233)
3*10
25
Joint 8*10
25
rs361367 7 C/T TCRVB SNP 0.42 21(25, 3) 0.57
CNV 0.02 252
(266, 231)
6*10
25
Joint 2*10
24
rs13003829 2 A/G ARHGEF4 SNP 0.21 1 (24, 5) 0.77
CNV 0.02 247
(263, 226)
3*10
24
Joint 1*10
23
rs12509348 4 A/G DCK SNP 0.17 23( 28, 2) 0.25
CNV 0.02 74 (25, 240) 9*10
24
Joint 1*10
23
{For more detailed information about these markers see Table S1.
{A1 is the modeled/minor allele for which frequency (freq) is reported.
*nearest gene within a 200 kb window on either side of the marker (if gene is
italicized the marker lies in the gene).
doi:10.1371/journal.pone.0024052.t002
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The screening model included an analysis of genotypes with a set
of residuals derived from a model of the phenotype adjusted for
non-genetic factors. We then re-analyzed the most significant loci
derived from the screening model using the full model adjusted for
genetic and non-genetic factors. Aulchenko et al. [29] reported that
the analysis of the residuals alone for a quantitative trait is
conservative compared to the full model and supported the re-
analysis of the full model for markers that reach a pre-defined
significance threshold. Our results support use of this two-stage
procedure. For example Figure S2 is the Quantile-Quantile (QQ)
plot of observed versus expected P-values from the screening
model for fasting insulin and portrays how the residual models do
not reach the expected significance under the null hypothesis for a
wide range of markers. We chose, a priori, to re-analyze 1,000 loci
with the full model and could have missed interesting markers with
this approach. However, we felt this approach was conducive to
isolate potentially significant loci while preserving computational
efficiency. Finally, this study considered additive models of
inheritance which have been proposed as the most powerful
approach for the purposes of gene discovery in GWAS [51].
Future larger studies of replicated genetic effects may further
interrogate alternate modes of inheritance of risk loci useful for
predictive modeling and/or functional experiments [52].
Genomic studies hold the promise for early identification of risk
for insulin resistance and subsequent progression to type 2
diabetes. To our knowledge, this is the first GWAS of insulin
resistance in an African American population that combines SNP
and CNV data. The markers we identified have not been noted in
GWAS of European populations [16,35]. However, the most
significant SNP and CNV loci highlighted in our study are near
genes (ATP10A, TCRVB) that have been identified as playing a role
in T2D in vivo. We stress the need to replicate these findings in
additional African American cohorts with subsequent functional
experiments to fully characterize replicated effects. In conclusion,
this study highlights several interesting genomic regions associated
with measures of insulin resistance in the understudied African
American population. Future studies are needed to continue to
dissect the genetic architecture of diabetes and related traits in
African Americans.
Supporting Information
Figure S1 Eigenvalues associated with principal com-
ponents generated in Eigenstrat from genetic data on
1,040 African Americans from HyperGEN.
(TIF)
Figure S2 Fasting Insulin Quantile-Quantile (QQ) Plot
generated from the stage 1 analysis screening model.
(TIF)
Table S1 Expanded results for top 1000 loci associated
with fasting insulin [ln(mIU/mL)] and HOMA-IR in
African Americans without diabetes from HyperGEN.
Models are adjusted for age, sex, genetic admixture and family
relationship.
(XLS)
Table S2 Expanded results for top 1000 loci associated
with fasting insulin [ln(mIU/mL)] and HOMA-IR in
African Americans without diabetes from HyperGEN.
Models are extended from Table S1 to be additionally adjusted for
antihypertensive treatment (ACE inhibitor, calcium channel
blocker, diuretic) and BMI.
(XLS)
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